{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T04:15:28Z","timestamp":1790396128297,"version":"4.1.0"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2012,7,30]],"date-time":"2012-07-30T00:00:00Z","timestamp":1343606400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Acta Pharmacol Sin"],"published-print":{"date-parts":[[2012,8]]},"DOI":"10.1038\/aps.2012.75","type":"journal-article","created":{"date-parts":[[2012,7,30]],"date-time":"2012-07-30T09:02:21Z","timestamp":1343638941000},"page":"1013-1022","source":"Crossref","is-referenced-by-count":11,"title":["Acute and chronic administration of SHR117887, a novel and specific dipeptidyl peptidase-4 inhibitor, improves metabolic control in diabetic rodent models"],"prefix":"10.1038","volume":"33","author":[{"given":"Xiao","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li-na","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Qu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guo-qing","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Leng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2012,7,30]]},"reference":[{"key":"BFaps201275_CR1","doi-asserted-by":"publisher","first-page":"1954","DOI":"10.1172\/JCI105685","volume":"46","author":"MJ Perley","year":"1967","unstructured":"Perley MJ, Kipnis DM . Plasma insulin responses to oral and intravenous glucose: studies in normal and diabetic subjects. J Clin Invest 1967; 46: 1954\u201362.","journal-title":"J Clin Invest"},{"key":"BFaps201275_CR2","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.numecd.2007.05.004","volume":"18","author":"E Bonora","year":"2008","unstructured":"Bonora E . Protection of pancreatic beta\u2013cells: is it feasible? Nutr Metab Cardiovasc Dis 2008; 18: 74\u201383.","journal-title":"Nutr Metab Cardiovasc Dis"},{"key":"BFaps201275_CR3","doi-asserted-by":"publisher","first-page":"217","DOI":"10.2337\/dc09-S314","volume":"32","author":"S Del Prato","year":"2009","unstructured":"Del Prato S, Penno G, Miccoli R . Changing the treatment paradigm for type 2 diabetes. Diabetes Care 2009; 32: 217\u201322.","journal-title":"Diabetes Care"},{"key":"BFaps201275_CR4","doi-asserted-by":"publisher","first-page":"39","DOI":"10.3949\/ccjm.76.s5.06","volume":"76","author":"WT Cefalu","year":"2009","unstructured":"Cefalu WT, Richards RJ, Melendez-Ramircz LY . Redefining treatment success in type 2 diabetes mellitus: comprehensive targeting of core defects. Cleve Clin J Med 2009; 76: 39\u201347.","journal-title":"Cleve Clin J Med"},{"key":"BFaps201275_CR5","doi-asserted-by":"publisher","first-page":"223","DOI":"10.2337\/dc09-S315","volume":"32","author":"MA Nauck","year":"2009","unstructured":"Nauck MA, Vilsb\u00f8ll T, Gallwitz B, Garber A, Madsbad S . Incretin-based therapies: viewpoints on the way to consensus. Diabetes Care 2009; 32: 223\u201331.","journal-title":"Diabetes Care"},{"key":"BFaps201275_CR6","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1016\/j.pharmthera.2009.11.001","volume":"125","author":"AA Tahrani","year":"2010","unstructured":"Tahrani AA, Piya MK, Kennedy A, Barnett AH . Glycaemic control in type 2 diabetes: targets and new therapies. Pharmacol Ther 2010; 125: 328\u201361.","journal-title":"Pharmacol Ther"},{"key":"BFaps201275_CR7","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1002\/dmrr.328","volume":"18","author":"JJ Holst","year":"2002","unstructured":"Holst JJ . Therapy of type 2 diabetes mellitus based on the actions of glucagon-like peptide-1. Diabetes Metab Res Rev 2002; 18: 430\u201341.","journal-title":"Diabetes Metab Res Rev"},{"key":"BFaps201275_CR8","first-page":"473","volume":"82","author":"B Ahren","year":"1997","unstructured":"Ahren B, Larsson H, Holst JJ . Effects of glucagon-like peptide-1 on islet function and insulin sensitivity in noninsulin\u2013dependent diabetes mellitus. J Clin Endocrinol Metab 1997; 82: 473\u20138.","journal-title":"J Clin Endocrinol Metab"},{"key":"BFaps201275_CR9","first-page":"327","volume":"81","author":"B Willms","year":"1996","unstructured":"Willms B, Werner J, Holst JJ, Orskov C, Creutzfeldt W, Nauck MA . Gastric emptying, glucose responses and insulin secretion after a liquid test meal: effects of exogenous glucagon-like peptide-1 (GLP-1)-(7\u201336) amide in type 2 (noninsulin-dependent) diabetic patients. J Clin Endocrinol Metab 1996; 81: 327\u201332.","journal-title":"J Clin Endocrinol Metab"},{"key":"BFaps201275_CR10","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1038\/sj.ijo.0800818","volume":"23","author":"E Naslund","year":"1999","unstructured":"Naslund E, Barkeling B, King N, Gutniak M, Blundell JE, Holst JJ, et al. Energy intake and appetite are suppressed by glucagon-like peptide-1 (GLP-1) in obese men. Int J Obes Relat Metab Disord 1999; 23: 304\u201311.","journal-title":"Int J Obes Relat Metab Disord"},{"key":"BFaps201275_CR11","doi-asserted-by":"publisher","first-page":"2263","DOI":"10.1172\/JCI117225","volume":"93","author":"DA D'Alessio","year":"1994","unstructured":"D'Alessio DA, Kahn SE, Leusner CR, Ensinck JW . Glucagon\u2013like peptide 1 enhances glucose tolerance both by stimulation of insulin release and by increasing insulin-independent glucose disposal. J Clin Investig 1994; 93: 2263\u20136.","journal-title":"J Clin Investig"},{"key":"BFaps201275_CR12","doi-asserted-by":"publisher","first-page":"741","DOI":"10.2337\/diabetes.52.3.741","volume":"52","author":"JA Pospisilik","year":"2003","unstructured":"Pospisilik JA, Martin J, Doty T, Ehses JA, Pamir N, Lynn FC, et al. Dipeptidyl peptidase IV inhibitor treatment stimulates cell survival and islet neogenesis in streptozotocin-induced diabetic rats. Diabetes 2003; 52: 741\u201350.","journal-title":"Diabetes"},{"key":"BFaps201275_CR13","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.cmet.2006.01.004","volume":"3","author":"DJ Drucker","year":"2006","unstructured":"Drucker DJ . The biology of incretin hormones. Cell Metab 2006; 3: 153\u201365.","journal-title":"Cell Metab"},{"key":"BFaps201275_CR14","doi-asserted-by":"publisher","first-page":"5149","DOI":"10.1210\/en.2003-0323","volume":"144","author":"L Farilla","year":"2003","unstructured":"Farilla L, Bulotta A, Hirshberg B, Li Calzi S, Khoury N, Noushmehr H, et al. Glucagon-like peptide 1 inhibits cell apoptosis and improves glucose responsiveness of freshly isolated human islets. Endocrinology 2003; 144: 5149\u201358.","journal-title":"Endocrinology"},{"key":"BFaps201275_CR15","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1111\/j.1432-1033.1993.tb17986.x","volume":"214","author":"R Mentlein","year":"1993","unstructured":"Mentlein R, Gallwitz B, Schmidt WE . Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1 (7\u201336)amide, peptide histidine methionine and is responsible for their degradation in human serum. Eur J Biochem 1993; 214: 829\u201335.","journal-title":"Eur J Biochem"},{"key":"BFaps201275_CR16","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1124\/jpet.108.143966","volume":"328","author":"L Thomas","year":"2009","unstructured":"Thomas L, Tadayyon M, Mark M . Chronic treatment with the dipeptidyl peptidase-4 inhibitor BI1356 [(R)-8-(3-amino-piperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl) -3,7-dihydro-purine-2,6-dione] increases basal glucagon-like peptide-1 and improves glycemic control in diabetic rodent models. J Pharmacol Exp Ther 2009; 328: 556\u201363.","journal-title":"J Pharmacol Exp Ther"},{"key":"BFaps201275_CR17","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1124\/jpet.106.112805","volume":"319","author":"K Yamazaki","year":"2006","unstructured":"Yamazaki K, Yasuda N, Inoue T, Nagakura T, Kira K, Shinoda M, et al. 7-But-2-ynyl-9-(6-methoxy-pyridin-3-yl)-6-piperazin-1-yl-7,9-dihydro-purin-8-one is a novel competitive and selective inhibitor of dipeptidyl peptidase IV with an antihyperglycemic activity. J Pharmacol Exp Ther 2006; 319: 1253\u20137.","journal-title":"J Pharmacol Exp Ther"},{"key":"BFaps201275_CR18","doi-asserted-by":"publisher","first-page":"5025","DOI":"10.1021\/jm050261p","volume":"48","author":"DJ Augeri","year":"2005","unstructured":"Augeri DJ, Robl JA, Betebenner DA, Magnin DR, Khanna A, Robertson JG, et al. Discovery and preclinical profile of saxagliptin (BMS-477118): a highly potent, long-acting, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. J Med Chem 2005; 48: 5025\u201337.","journal-title":"J Med Chem"},{"key":"BFaps201275_CR19","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1016\/j.ejphar.2008.04.018","volume":"588","author":"Y Moritoh","year":"2008","unstructured":"Moritoh Y, Takeuchi K, Asakawa T, Kataoka O, Odaka H . Chronic administration of alogliptin, a novel, potent, and highly selective dipeptidyl peptidase-4 inhibitor, improves glycemic control and beta-cell function in obese diabetic ob\/ob mice. Eur J Pharmacol 2008; 588: 325\u201332.","journal-title":"Eur J Pharmacol"},{"key":"BFaps201275_CR20","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1111\/j.1463-1326.2009.01180.x","volume":"12","author":"Y Furuta","year":"2010","unstructured":"Furuta Y, Horiguchi M, Sugaru E, Ono-Kishino M, Otani M, Sakai M, et al. Chronic administration of DSP-7238, a novel, potent, specific and substrate-selective DPP IV inhibitor, improves glycaemic control and \u03b2-cell damage in diabetic mice. Diabetes Obes Metab 2010; 12: 421\u201330.","journal-title":"Diabetes Obes Metab"},{"key":"BFaps201275_CR21","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1124\/jpet.107.135723","volume":"325","author":"L Thomas","year":"2008","unstructured":"Thomas L, Eckhardt M, Langkopf E, Tadayyon M, Himmelsbach F, Mark M . (R)-8-(3-Amino-piperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydro-purine-2,6-dione (BI1356), a novel xanthine-based dipeptidyl peptidase 4 inhibitor, has a superior potency and longer duration of action compared with other dipeptidyl peptidase-4 inhibitors. J Pharmacol Exp Ther 2008; 325: 175\u201382.","journal-title":"J Pharmacol Exp Ther"},{"key":"BFaps201275_CR22","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1111\/j.1742-1241.2006.01246.x","volume":"61","author":"R Scott","year":"2007","unstructured":"Scott R, Wu M, Sanchez M, Stein P . Efficacy and tolerability of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy over 12 weeks in patients with type 2 diabetes. Int J Clin Pract 2007; 61: 171\u201380.","journal-title":"Int J Clin Pract"},{"key":"BFaps201275_CR23","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.diabres.2006.12.009","volume":"76","author":"FX Pi-Sunyer","year":"2007","unstructured":"Pi-Sunyer FX, Schweizer A, Mills D, Dejager S . Efficacy and tolerability of vildagliptin monotherapy in drug-naive patients with type 2 diabetes. Diabetes Res Clin Practice 2007; 76: 132\u20138.","journal-title":"Diabetes Res Clin Practice"},{"key":"BFaps201275_CR24","doi-asserted-by":"publisher","first-page":"2315","DOI":"10.2337\/dc08-1035","volume":"31","author":"RA DeFronzo","year":"2008","unstructured":"DeFronzo RA, Fleck PR, Wilson CA, Mekki Q . Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes and inadequate glycemic control. Diabetes Care 2008; 31: 2315\u20137.","journal-title":"Diabetes Care"},{"key":"BFaps201275_CR25","doi-asserted-by":"publisher","first-page":"2774","DOI":"10.1021\/jm030091l","volume":"46","author":"EB Villhauer","year":"2003","unstructured":"Villhauer EB, Brinkman JA, Naderi GB, Burkey BF, Dunning BE, Prasad K, et al. 1-[(3-Hydroxy-1-adamantyl)amino]acetyl]-2-cyano-(S)-pyrrolidine: a potent, selective and orally bioavailable dipeptidyl peptidase IV inhibitor with antihyperglycemic properties. J Med Chem 2003; 46: 2774\u201389.","journal-title":"J Med Chem"},{"key":"BFaps201275_CR26","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1124\/jpet.105.087064","volume":"315","author":"BF Burkey","year":"2005","unstructured":"Burkey BF, Li X, Bolognese L, Balkan B, Mone M, Russell M, et al. Acute and chronic effects of the incretin enhancer vildagliptin in insulin-resistant rats. J Pharmacol Exp Ther 2005; 315: 688\u201395.","journal-title":"J Pharmacol Exp Ther"},{"key":"BFaps201275_CR27","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1185\/030079906X162746","volume":"23","author":"RE Pratley","year":"2007","unstructured":"Pratley RE, Salsali A . Inhibition of DPP-4: a new therapeutic approach for the treatment of type 2 diabetes. Curr Med Res Opin 2007; 23: 919\u201331.","journal-title":"Curr Med Res Opin"},{"key":"BFaps201275_CR28","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1254\/jjp.88.442","volume":"88","author":"H Mitani","year":"2002","unstructured":"Mitani H, Takimoto M, Hughes TE, Kimura M . Dipeptidyl peptidase IV inhibition improves impaired glucose tolerance in high-fat diet-fed rats: study using a Fischer 344 rat substrain deficient in its enzyme activity. Jpn J Pharmacol 2002; 88: 442\u201350.","journal-title":"Jpn J Pharmacol"},{"key":"BFaps201275_CR29","unstructured":"Herberg L, Leiter EH . Obesity\/diabetes in mice with mutations in the leptin or leptin receptor genes. In: Shima AAF, Shafrir E, editors. Animal models of diabetes a primer. Amsterdam: Harwood Academic Publishers; 2001. p 63\u2013107."},{"key":"BFaps201275_CR30","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.2337\/diab.47.8.1253","volume":"47","author":"RA Pederson","year":"1998","unstructured":"Pederson RA, White HA, Schlenzig D, Pauly RP, McIntosh CH, Demuth HU . Improved glucose tolerance in Zucker fatty rats by oral administration of the dipeptidyl peptidase IV inhibitor isoleucine thiazolidide. Diabetes 1998; 47: 1253\u20138.","journal-title":"Diabetes"},{"key":"BFaps201275_CR31","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1007\/s001250051445","volume":"42","author":"B Balkan","year":"1999","unstructured":"Balkan B, Kwasnik L, Miserendino R, Holst JJ, Li X . Inhibition of dipeptidyl peptidase IV with NVP-DPP728 increases plasma GLP-1 (7\u201336 amide) concentrations and improves oral glucose tolerance in obese Zucker rats. Diabetologia 1999; 42: 1324\u201331.","journal-title":"Diabetologia"},{"key":"BFaps201275_CR32","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/S0014-2999(00)00600-2","volume":"404","author":"B Ahren","year":"2000","unstructured":"Ahren B, Holst JJ, Martensson H, Balkan B . Improved glucose tolerance and insulin secretion by inhibition of dipeptidyl peptidase IV in mice. Eur J Pharmacol 2000; 404: 239\u201345.","journal-title":"Eur J Pharmacol"},{"key":"BFaps201275_CR33","doi-asserted-by":"publisher","first-page":"1695","DOI":"10.2337\/db05-1602","volume":"55","author":"J Mu","year":"2006","unstructured":"Mu J, Woods J, Zhou YP, Roy RS, Li Z, Zycband E, et al. Chronic inhibition of dipeptidyl peptidase-4 with a sitagliptin analog preserves pancreatic beta-cell mass and function in a rodent model of type 2 diabetes. Diabetes 2006; 55: 1695\u2013704.","journal-title":"Diabetes"},{"key":"BFaps201275_CR34","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1016\/j.ejphar.2008.04.018","volume":"588","author":"Y Moritoh","year":"2008","unstructured":"Moritoh Y, Takeuchi K, Asakawa T, Kataoka O, Odaka H . Chronic administration of alogliptin, a novel, potent, and highly selective dipeptidyl peptidase-4 inhibitor, improves glycemic control and beta-cell function in obese diabetic ob\/ob mice. Eur J Pharmacol 2008; 588: 325\u201332.","journal-title":"Eur J Pharmacol"},{"key":"BFaps201275_CR35","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1111\/j.1476-5381.2009.00145.x","volume":"157","author":"Y Moritoh","year":"2009","unstructured":"Moritoh Y, Takeuchi K, Asakawa T, Kataoka O, Odaka H . Combining a dipeptidyl peptidase-4 inhibitor, alogliptin, with pioglitazone improves glycaemic control, lipid profiles and \u03b2-cell function in db\/db mice. Br J Pharmacol 2009; 157: 415\u201326.","journal-title":"Br J Pharmacol"},{"key":"BFaps201275_CR36","doi-asserted-by":"publisher","first-page":"1695","DOI":"10.2337\/db05-1602","volume":"55","author":"J Mu","year":"2006","unstructured":"Mu J, Woods J, Zhou YP, Roy RS, Li Z, Zycband E, et al. Chronic inhibition of dipeptidyl peptidase-4 with a sitagliptin analog preserves pancreatic beta-cell mass and function in a rodent model of type 2 diabetes. Diabetes 2006; 55: 1695\u2013704.","journal-title":"Diabetes"},{"key":"BFaps201275_CR37","doi-asserted-by":"publisher","first-page":"1936","DOI":"10.1210\/endo.141.6.7490","volume":"141","author":"M Szayna","year":"2000","unstructured":"Szayna M, Doyle ME, Betkey JA, Holloway HW, Spencer RG, Greig NH, et al. Exendin-4 decelerates food intake, weight gain, and fat deposition in Zucker rats. Endocrinology 2000; 141: 1936\u201341.","journal-title":"Endocrinology"},{"key":"BFaps201275_CR38","doi-asserted-by":"publisher","first-page":"1448","DOI":"10.1016\/j.clinthera.2008.08.006","volume":"30","author":"TJ Moretto","year":"2008","unstructured":"Moretto TJ, Milton DR, Ridge TD, Macconell LA, Okerson T, Wolka AM, et al. Efficacy and tolerability of exenatide monotherapy over 24 weeks in antidiabetic drug-naive patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, parallel-group study. Clin Ther 2008; 30: 1448\u201360.","journal-title":"Clin Ther"},{"key":"BFaps201275_CR39","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1111\/j.1464-5491.2005.01567.x","volume":"22","author":"MN Feinglos","year":"2005","unstructured":"Feinglos MN, Saad MF, Pi\u2013Sunyer FX, An B, Santiago O . Effects of liraglutide (NN2211), a long-acting GLP-1 analogue, on glycaemic control and body weight in subjects with type 2 diabetes. Diabet Med 2005; 22: 1016\u201323.","journal-title":"Diabet Med"}],"container-title":["Acta Pharmacologica Sinica"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/aps201275.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/aps201275","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/aps201275.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T12:28:39Z","timestamp":1684412919000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/aps201275"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,7,30]]},"references-count":39,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2012,8]]}},"alternative-id":["BFaps201275"],"URL":"https:\/\/doi.org\/10.1038\/aps.2012.75","relation":{},"ISSN":["1671-4083","1745-7254"],"issn-type":[{"value":"1671-4083","type":"print"},{"value":"1745-7254","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,7,30]]}}}